Latest Insider Transactions at Selecta Biosciences Inc (SELB)
This section provides a real-time view of insider transactions for Selecta Biosciences Inc (SELB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SELECTA BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SELECTA BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2024
|
Elizabeth Hoge > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,418,617
+49.17%
|
-
|
|
Mar 26
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,970,443
+5.63%
|
$1,970,443
$1.46 P/Share
|
|
Mar 18
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
19,844
+0.41%
|
$0
$0.61 P/Share
|
|
Mar 15
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
538,700
+1.42%
|
$0
$0.58 P/Share
|
|
Mar 14
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
650,372
+1.99%
|
$0
$0.54 P/Share
|
|
Mar 13
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
3,200
+3.08%
|
$0
$0.58 P/Share
|
|
Mar 12
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+1.21%
|
$0
$0.61 P/Share
|
|
Mar 11
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
1,200
+1.23%
|
$0
$0.65 P/Share
|
|
Mar 08
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
4,800
+4.8%
|
$0
$0.66 P/Share
|
|
Feb 07
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
2,400
+2.59%
|
$0
$0.66 P/Share
|
|
Feb 06
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
800
+0.9%
|
$0
$0.65 P/Share
|
|
Jan 17
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
800
+0.91%
|
$0
$0.69 P/Share
|
|
Jan 02
2024
|
Michael Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+38.19%
|
-
|
|
Jan 02
2024
|
Patrick J Zenner Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+43.28%
|
-
|
|
Jan 02
2024
|
Carrie Smith Cox Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+31.29%
|
-
|
|
Jan 02
2024
|
Nishan M De Silva Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+49.04%
|
-
|
|
Jan 02
2024
|
Milos Miljkovic Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
548,200
+50.0%
|
-
|
|
Jan 02
2024
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+2.33%
|
-
|
|
Jan 02
2024
|
Timothy C Barabe Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+29.37%
|
-
|
|
Jan 02
2024
|
Aymeric Sallin Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+50.0%
|
-
|
|
Jan 02
2024
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,654,100
+48.63%
|
-
|
|
Jan 02
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
778,200
+50.0%
|
-
|
|
Jan 02
2024
|
Blaine Davis Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,424,000
+50.0%
|
-
|
|
Jan 02
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,531,000
+50.0%
|
-
|
|
Jan 02
2024
|
Murat Kalayoglu Director |
BUY
Grant, award, or other acquisition
|
Direct |
178,000
+29.0%
|
-
|
|
Nov 15
2023
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,925
+50.0%
|
$49,941,775
$403.47 P/Share
|
|
Nov 15
2023
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Indirect |
24,785
+50.0%
|
$9,988,355
$403.47 P/Share
|
|
Nov 13
2023
|
Carsten Brunn President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
521,125
-21.14%
|
$1,042,250
$2.06 P/Share
|
|
Nov 13
2023
|
Murat Kalayoglu Director |
BUY
Other acquisition or disposition
|
Indirect |
3,303,699
+50.0%
|
-
|
|
Nov 13
2023
|
Murat Kalayoglu Director |
BUY
Grant, award, or other acquisition
|
Direct |
257,739
+50.0%
|
-
|
|
Nov 13
2023
|
Michael Singer Director |
BUY
Other acquisition or disposition
|
Indirect |
337,271
+50.0%
|
-
|
|
Nov 13
2023
|
Michael Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
110,123
+50.0%
|
-
|
|
Sep 25
2023
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
705
-0.16%
|
$705
$1.06 P/Share
|
|
Sep 25
2023
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
2,932
-0.37%
|
$2,932
$1.06 P/Share
|
|
May 31
2023
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
53,000
-10.02%
|
-
|
|
May 30
2023
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
86,000
-12.59%
|
-
|
|
Jan 05
2023
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,465
-0.39%
|
$3,465
$1.12 P/Share
|
|
Jan 05
2023
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,392
-0.46%
|
$3,392
$1.12 P/Share
|
|
Jan 05
2023
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
3,392
-0.63%
|
$3,392
$1.12 P/Share
|
|
Jan 05
2023
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
13,473
-0.84%
|
$13,473
$1.13 P/Share
|
|
Jan 04
2023
|
Peter G Traber Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,179
-0.89%
|
$8,179
$1.14 P/Share
|
|
Jan 04
2023
|
Takashi Kei Kishimoto Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,392
-0.85%
|
$6,392
$1.14 P/Share
|
|
Jan 04
2023
|
Lloyd P. Johnston Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
6,392
-1.16%
|
$6,392
$1.14 P/Share
|
|
Jan 04
2023
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
27,597
-1.67%
|
$27,597
$1.14 P/Share
|
|
Jan 02
2023
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+21.09%
|
-
|
|
Jan 02
2023
|
Lloyd P. Johnston Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+26.65%
|
-
|
|
Jan 02
2023
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
282,800
+25.48%
|
-
|
|
Jan 02
2023
|
Peter G Traber Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+30.41%
|
-
|
|
Dec 05
2022
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,522
-0.82%
|
$4,522
$1.33 P/Share
|
|
Dec 01
2022
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+1.95%
|
-
|